PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of this study was to verify TCGA subtypes in endometrial clear cell carcinoma (ECCC) and determine their clinical and molecular characteristics.
UNASSIGNED: We summarized and compared the clinical features of 28 clear cell carcinoma and 112 endometrioid carcinoma patients. Of the 28 ECCCs, 19 underwent TCGA classification, and other markers (ER, PR, ARID1A, ARIB1B, TAF1, and HER-2) were also detected by IHC, and outcomes were assessed.
UNASSIGNED: Compared to endometrioid carcinoma, ECCC had an older age of onset (median age, 64.5 years, range 31-81 years), higher rate of myometrial invasion (42.8% vs. 21.5% in endometrioid carcinoma), LVSI (33% vs. 16%), and more advanced FIGO stage. Among the ECCCs, LVSI was a poor prognostic factor. TCGA classification was performed for 19 ECCCs: two POLEmut cases (10.5%), three MMRd (15.8%), 11 p53wt (57.9%), and three p53abn (15.8%). Of the 19 ECCCs, six (31.6%) showed HER-2 positive expression, and eight (42.1%) had TAF1 expression loss. ECCCs possessed HER-2 and TAF1 expression had worse outcomes.
UNASSIGNED: Our study summarized the clinical features of ECCC. The outcomes of patients with ECCC with TCGA subtypes differed from those of patients with endometrioid carcinoma. HER-2 and TAF1 may be new prognostic factors.
UNASSIGNED: We summarized and compared the clinical features of 28 clear cell carcinoma and 112 endometrioid carcinoma patients. Of the 28 ECCCs, 19 underwent TCGA classification, and other markers (ER, PR, ARID1A, ARIB1B, TAF1, and HER-2) were also detected by IHC, and outcomes were assessed.
UNASSIGNED: Compared to endometrioid carcinoma, ECCC had an older age of onset (median age, 64.5 years, range 31-81 years), higher rate of myometrial invasion (42.8% vs. 21.5% in endometrioid carcinoma), LVSI (33% vs. 16%), and more advanced FIGO stage. Among the ECCCs, LVSI was a poor prognostic factor. TCGA classification was performed for 19 ECCCs: two POLEmut cases (10.5%), three MMRd (15.8%), 11 p53wt (57.9%), and three p53abn (15.8%). Of the 19 ECCCs, six (31.6%) showed HER-2 positive expression, and eight (42.1%) had TAF1 expression loss. ECCCs possessed HER-2 and TAF1 expression had worse outcomes.
UNASSIGNED: Our study summarized the clinical features of ECCC. The outcomes of patients with ECCC with TCGA subtypes differed from those of patients with endometrioid carcinoma. HER-2 and TAF1 may be new prognostic factors.
摘要：
■这项研究的目的是验证子宫内膜透明细胞癌（ECCC）中的TCGA亚型，并确定其临床和分子特征。
■我们总结并比较了28例透明细胞癌和112例子宫内膜样癌患者的临床特征。在28个ECCC中，19人接受了TCGA分类，和其他标记（ER，PR,ARID1A,ARIB1B,TAF1和HER-2）也通过IHC检测到，并对结果进行了评估。
■与子宫内膜样癌相比，ECCC的发病年龄较大(中位年龄，64.5年,范围31-81年)，子宫肌层浸润率较高（42.8%vs.子宫内膜样癌占21.5％），LVSI（33%与16%），和更先进的FIGO阶段。在ECCC中，LVSI是不良预后因素。对19例ECCC进行了TCGA分类：2例POLEmut病例（10.5％），三个MMRd（15.8%），11p53wt（57.9%），和三个p53abn（15.8%）。在19个ECCC中，6例(31.6%)HER-2阳性表达,8例(42.1%)TAF1表达缺失。ECCC具有HER-2和TAF1表达的结果较差。
■我们的研究总结了ECCC的临床特征。具有TCGA亚型的ECCC患者的预后与子宫内膜样癌患者的预后不同。HER-2和TAF1可能是新的预后因子。
■我们总结并比较了28例透明细胞癌和112例子宫内膜样癌患者的临床特征。在28个ECCC中，19人接受了TCGA分类，和其他标记（ER，PR,ARID1A,ARIB1B,TAF1和HER-2）也通过IHC检测到，并对结果进行了评估。
■与子宫内膜样癌相比，ECCC的发病年龄较大(中位年龄，64.5年,范围31-81年)，子宫肌层浸润率较高（42.8%vs.子宫内膜样癌占21.5％），LVSI（33%与16%），和更先进的FIGO阶段。在ECCC中，LVSI是不良预后因素。对19例ECCC进行了TCGA分类：2例POLEmut病例（10.5％），三个MMRd（15.8%），11p53wt（57.9%），和三个p53abn（15.8%）。在19个ECCC中，6例(31.6%)HER-2阳性表达,8例(42.1%)TAF1表达缺失。ECCC具有HER-2和TAF1表达的结果较差。
■我们的研究总结了ECCC的临床特征。具有TCGA亚型的ECCC患者的预后与子宫内膜样癌患者的预后不同。HER-2和TAF1可能是新的预后因子。
